Condition: Hereditary Spastic Paraplegia · Sponsor: IRCCS Fondazione Stella Maris
Our goal is to create a solid and harmonious disease registry of patient affected by hereditary spastic paraplegia (HSP) that facilitates the collection and management of patients' data over time encouraging the research and the development of future clinical trials. In-depth clinical phenotyping will develop significant clinical outcome measures that can be used in clinical trials and will allow the phenotypic complexity of the disease to be captured with the use of validated clinical scales, biomarkers and so-called patient reported outcomes (PROs).
This description comes directly from the study's public registry record.
Filippo M Santorelli, Dr. · +39 050886275 · filippo.santorelli@fsm.unipi.it
Sara Satolli, Dr. · sara.satolli@fsm.unipi.it
Always discuss trial participation with your own doctor first.
| IRCCS Fondazione Stella Maris | Pisa, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06572046